Drug intelligence / Profile preview

SOSA

Development stage: Unknown
Lead developer: Nirvana Life Sciences

Overview

**SOSA** is a proprietary herbal medicine marketed for opioid dependence, opioid detoxification, and acute opioid withdrawal. Nirvana Life Sciences acquired Medsmart Dispensary, the exclusive North American licensee, and subsequently reported receipt of a first North American production shipment for planned analytical work and preclinical studies. Public company disclosures characterize SOSA as a patented herbal treatment that has been used in several Asian countries; however, they do not disclose its botanical composition, active constituents, dosage form, route, molecular target, or a defined pharmacologic mechanism of action. ([newsfilecorp.com](https://www.newsfilecorp.com/release/195855/Nirvana-Life-Sciences-Inc.-Announces-Receipt-of-First-North-American-Production-of-SOSA-a-Patented-WHO-Approved-Herbal-Treatment-for-Opiate-Addiction))

Brand names: SOSA

Beyond the preview

Go deeper on SOSA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOSA.

Explore the full profile